Rasio rega marang prakiraan pendapatan Vir Corp (VIR)

The success of Vir Biotechnology, Inc. (VIR) depends on the commercial implementation of hepatitis antibodies in collaboration with partners. The forward P/S based on forecasts allows for an assessment of market expectations, while 5.60 expresses the current value of this metric. The business is not subject to economic cycles thanks to substantial cash reserves. The company's revenues are based on grants, royalties, and the commercialization of its own immunological developments.

VIR (vir.bio) riwayat Rega forward marang dodolan saka 04.07.2022 nganti 14.11.2026

Rincian analitis perusahaan Vir Biotechnology, Inc.

- rega saiki lan proyeksi nilai saham:

Rega saham Vir Biotechnology|VIR - Target median analis

- rincian kapitalisasi pasar:

Nilai pasar Vir Corp|VIR - Nilai Dipunlarasaken Utang lan Kas

- indikator nilai buku ekuitas:

Nilai Akuntansi saben Saham Vir Biotechnology|VIR - Nilai Akuntansi Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku vir.bio|VIR - Aset Agregat Perusahaan

- informasi babagan utang lan solvabilitas:

- indikator pendapatan resik lan kelipatan nilai:

VIR - Penghasilan resik|Proyeksi bathi mangsa ngarep Vir Biotechnology, Inc.|VIR - Nilai perusahaan marang bathi resik|Rega marang bathi mangsa ngarep Vir Bio|VIR - Rasio P/E diaturake wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Vir Corp|VIR - Bathi sadurunge bunga, pajak, lan amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Vir Biotechnology|VIR - Bathi saben saham sajrone rolas wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan vir.bio|VIR - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Vir Biotechnology, Inc.

- statistik dodolan lan pendapatan perusahaan:

VIR - Total volume dodolan perusahaan|Volume dodolan mangsa ngarep perusahaan Vir Biotechnology|VIR - Rega marang dodolan|Multiplikator forward rega marang pendapatan Vir Corp

Analisis wiwitan perusahaan:Vir Biotechnology (VIR)

The forward P/S ratio assesses the market value of a business relative to expected revenue, determining the extent of the premium paid for future success. Analyzing the expected P/S value allows for a comparison of current market capitalization against projected sales volumes. This metric is calculated as the ratio of the share price to the predicted revenue per share. For Vir Biotechnology, Inc. (VIR), this indicator remains stable, as massive cash reserves ensure that research remains independent of economic cycles.

Perusahaan pesaing

Multiplikator Forward P/S GILD (Gilead Sciences)|Rasio kapitalisasi marang dodolan sing dikarepake Cidara Therapeutics Corp (CDTX)|NVAX - Rasio rega marang prakiraan pendapatan|Rega forward marang dodolan CVAC (CureVac Pharma)|VALN (Valneva SE) - Multiplikator forward rega marang pendapatan|siga.com - Rega forward marang dodolan|EBS (Emergent BioSolutions Inc.) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan AVIR|Multiplikator Forward P/S IVVD|Rasio kapitalisasi marang dodolan sing dikarepake Enanta Pharmaceuticals, Inc|Rasio rega marang prakiraan pendapatan Inovio Pharmaceuticals INO|hillevax.com (HLVX) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|KLRS: Multiplikator forward rega marang pendapatan|Dyadic International - Rasio rega marang pendapatan sing dikarepake|NNVC: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Talphera Corporation (TLPH)|COCP (Cocrystal Pharma, Inc.) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Traws Therapeutics (TRAW)|Multiplikator Forward P/S DWTX|QLGN (Qualigen Therapeutics Inc) - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan AlloVir ALVR|VBIV: Kapitalisasi marang prakiraan pendapatan|VIRI - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Vaxart, Inc.